Drug sales post healthy gains for 2006, but primary care categories slip

Share this article:
Global pharmaceutical sales grew 7% to $643 billion in 2006, according to IMS Health, while US drug sales were up 8.3% to $290.1 billion for the year, thanks to Medicare Part D and strong sales of specialty products -- particularly oncologics and autoimmune agents. Specialist-driven products contributed 62% of growth, compared with just 35% in 2000, the company said. Sales of oncologics were up 20.5% to $34.6 billion, with more than 380 compounds in development, including many targeted therapies in Phase III clinical trials. Autoimmune agents like Remicade and Humira were up 20% to $10.6 billion in sales, with a boost from new indications approved for existing medications. Respiratory drug sales were up 10% to $24.6 billion, and sales of lipid drugs continued to grow, up 7.5% to $35.2 billion. But some long-reliable primary care cash cows slipped due to generic incursions and OTC switches, with PPIs, antihistamines, platelet aggregation inhibitors and antidepressants losing ground. And products worth $14 billion in US sales lost patent protection over the course of the year.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions